Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
DCTH
Strong BuyPremium GrowerDelcath Systems, Inc. · Healthcare · United States · $567M · Avg Vol: $10M/d
COMPANY DESCRIPTION
Delcath Systems, Inc. is a commercial-stage oncology company focused on developing and commercializing its proprietary Melphalan Hepatic Delivery System (Melphalan/HDS) for treating primary and metastatic cancers of the liver. The company's unique drug-device combination allows for targeted regional chemotherapy, offering a specialized treatment option for liver-dominant cancers with reduced systemic toxicity.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.7M | 2.1M | 37.2M | 85.2M | 215.3% | 95.4M | 106.2M | 132.0M | 24.4% |
| EPS | -1.20 | -2.94 | -0.93 | 0.08 | — | 0.01 | — | — | — |
| Shares | 34.5M | 22.8M | 33.1M | 34.7M | +0.5% | 34.7M | — | — | — |
| Debt | 15.9M | 10.2M | 1.0M | 0.9M | -61.1% | 2.5M | — | — | — |
| Equity | -5.9M | 15.8M | 68.7M | 111.2M | 165.5% | — | — | — | — |
| Op CF | -24.9M | -31.3M | -18.7M | 22.5M | — | 19.6M | — | — | — |
| Inv CF | -0.2M | -19.7M | -1.0M | -26.6M | — | — | — | — | — |
| Fin CF | 10.1M | 51.8M | 39.4M | 15.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DCTH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DCTH | Delcath Systems, Inc.(you) | $567M | 87 | Strong Buy |
| TCMD | Tactile Systems Technology, Inc. | $525M | 87 | Strong Buy |
| VMD | Viemed Healthcare, Inc. | $336M | 87 | Strong Buy |
| ELMD | Electromed, Inc. | $248M | 88 | Strong Buy |
| BVS | Bioventus Inc. | $945M | 96 | Strong Buy |
| CNMD | CONMED Corporation | $1.5B | 87 | Strong Buy |
| VREX | Varex Imaging Corporation | $780M | 71 | Buy |
| INSP | Inspire Medical Systems, Inc. | $1.8B | 83 | Strong Buy |
| IART | Integra LifeSciences Holdings Corporation | $1.3B | 75 | Buy |
| IRMD | IRADIMED CORPORATION | $1.1B | 65 | Buy |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.1%